Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01009840 · ClinicalTrials.gov registry record · Phase 2
IV Busulfan Plus Bortezomib Conditioning Regimen for Second Autologous Stem Cell Transplant in Multiple Myeloma Patients
A Phase 2 study of Multiple Myeloma, sponsored by Otsuka Pharmaceutical Development & Commercialization.
- Completed
- Registry status
- Phase 2
- Development phase
- 30
- Enrollment target
- 13
- Study locations
NCT01009840 is a Phase 2 study of Multiple Myeloma that has completed, run by Otsuka Pharmaceutical Development & Commercialization. The registered enrollment target is 30 participants, below the 547-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (95% lower). The trial reports 13 study locations across 11 states.
The verdict
NCT01009840, a Phase 2 study of Multiple Myeloma, has completed, sponsored by Otsuka Pharmaceutical Development & Commercialization.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 30 participants
- Enrollment target
- 13
- Study locations
Study Summary
Study for the outcome and safety of individualized busulfan dosing with bortezomib for patients preparing for a second stem cell transplant to treat multiple myeloma.
Conditions Studied
Interventions
- DRUG bortezomib
- DRUG IV busulfan
- PROCEDURE Autologous Hematopoietic Stem Cell Transplant (HSCT)
Study Locations (13)
Pennsylvania
- University of Pennsylvania -Abramson Cancer Center - Philadelphia
- The Western Pennsylvania Hospital - Pittsburgh
Texas
- South Texas Veterans Health Care System - San Antonio
- Texas Transplant Physician Group, PLLC - San Antonio
Arizona
- Arizona Cancer Center - Tucson
Georgia
- Blood and Marrow Transplant Group of Georgia - Atlanta
Illinois
- Loyola University Medical Center - Maywood
Indiana
- Indiana University Melvin and Bren Simon Cancer Center - Indianapolis
Maryland
- University of Maryland School of Medicine - Marlene & Stewart Greenebaum Cancer Center - Baltimore
Michigan
- Karmanos Cancer Institute - Detroit
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2010-05 |
| Est. Completion | 2012-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01009840
The ClinicalTrials.gov registry entry for NCT01009840 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 547-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (95% lower). The listed sponsor is Otsuka Pharmaceutical Development & Commercialization, which has 221 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Multiple Myeloma appearing as the primary indexed condition, and to 3 interventions - of which bortezomib is the first listed.
NCT01009840 reports 13 study locations spanning 11 distinct geographic areas - top geographies include Pennsylvania, Texas, Arizona.
Frequently Asked Questions
What is clinical trial NCT01009840 about?
NCT01009840 is a clinical study titled "IV Busulfan Plus Bortezomib Conditioning Regimen for Second Autologous Stem Cell Transplant in Multiple Myeloma Patients". Study for the outcome and safety of individualized busulfan dosing with bortezomib for patients preparing for a second stem cell transplant to treat multiple myeloma.
What is the current status of trial NCT01009840?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2010-05. Estimated completion is 2012-03.
What conditions does trial NCT01009840 study?
This clinical trial studies the following conditions: Multiple Myeloma.
What interventions are being tested in trial NCT01009840?
The interventions under investigation include: bortezomib (DRUG), IV busulfan (DRUG), Autologous Hematopoietic Stem Cell Transplant (HSCT) (PROCEDURE).
Who is sponsoring clinical trial NCT01009840?
This trial is sponsored by Otsuka Pharmaceutical Development & Commercialization, which has 221 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01009840 being conducted?
This trial has 13 study locations across Arizona, Georgia, Illinois, Indiana, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multiple Myeloma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of Whether Ide-cel (bb2121) Can Be Made From People With Multiple Myeloma Who Have Had a Hematopoietic Cell Transplant
RECRUITING · Phase 2
-
A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma
RECRUITING · Phase 2
-
Isa-Rd for Frail and/or Much Older Patients With Newly Diagnosed Multiple Myeloma
RECRUITING · Phase 2
-
CAR T-cell Therapy in Patients With Renal Dysfunction
RECRUITING · Phase 2
-
IMMUNOPLANT for Newly Diagnosed Multiple Myeloma
RECRUITING · Phase 2
-
Nivolumab in Multiple Myeloma Patients After Idecabtagene Vicleucel
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.